AGC Biologics purchases cell and gene therapy facility in Colorado

AGC Biologics, a contract development and manufacturing organization (CDMO), has finalized a deal to purchase a state-of-the-art commercial manufacturing facility in Longmont, CO. The facility, which had been previously owned by Novartis Gene Therapies, will provide AGC Biologics with 622,000 square feet of additional capacity to grow its global end-to-end cell and gene therapy (C&GT) offering.

The facility is expected to begin full-scale operations by Q4 of this year.

The transaction, says the CDMO, is also expected to enable AGC to continue expanding its process development and good manufacturing practice (GMP) capacity to fulfill both early and late clinical/commercial customer needs.

Aside from this facility acquisition, AGC has had other C&GT expansion projects, including one at its Heidelberg, Germany site in 2020—the location which is supplying plasmid DNA (pDNA) starting material for the Pfizer-BioNTech Covid-19 vaccine—and one at its Milan, Italy facility earlier this year.